| Combination therapy with anti-HIV-1 antibodies maintains viral suppression P Mendoza, H Gruell, L Nogueira, JA Pai, AL Butler, K Millard, ... Nature 561 (7724), 479-484, 2018 | 495 | 2018 |
| Antibody 10-1074 suppresses viremia in HIV-1-infected individuals M Caskey, T Schoofs, H Gruell, A Settler, T Karagounis, EF Kreider, ... Nature medicine 23 (2), 185-191, 2017 | 487 | 2017 |
| Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients C Hoffmann, T Welz, M Sabranski, M Kolb, E Wolf, HJ Stellbrink, C Wyen HIV medicine 18 (1), 56-63, 2017 | 324 | 2017 |
| Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide–based 3-or 4-drug regimen for maintenance of … J Van Wyk, F Ajana, F Bisshop, S De Wit, O Osiyemi, J Portilla Sogorb, ... Clinical Infectious Diseases 71 (8), 1920-1929, 2020 | 283 | 2020 |
| Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo … H Montgomery, FDR Hobbs, F Padilla, D Arbetter, A Templeton, ... The Lancet Respiratory Medicine 10 (10), 985-996, 2022 | 252 | 2022 |
| Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals Y Bar-On, H Gruell, T Schoofs, JA Pai, L Nogueira, AL Butler, K Millard, ... Nature medicine 24 (11), 1701-1707, 2018 | 248 | 2018 |
| Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients SK Barta, X Xue, D Wang, R Tamari, JY Lee, N Mounier, LD Kaplan, ... Blood, The Journal of the American Society of Hematology 122 (19), 3251-3262, 2013 | 227 | 2013 |
| Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients C Wyen, H Hendra, M Vogel, C Hoffmann, H Knechten, NH Brockmeyer, ... Journal of antimicrobial chemotherapy 61 (4), 914-918, 2008 | 210 | 2008 |
| Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease C Hoffmann, H Schmid, M Müller, C Teutsch, J Van Lunzen, S Esser, ... Blood, The Journal of the American Society of Hematology 118 (13), 3499-3503, 2011 | 141 | 2011 |
| Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing … C Wyen, H Hendra, M Siccardi, M Platten, H Jaeger, T Harrer, S Esser, ... Journal of antimicrobial chemotherapy 66 (9), 2092-2098, 2011 | 131 | 2011 |
| Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study M Hentrich, M Berger, C Wyen, J Siehl, JK Rockstroh, M Müller, ... Journal of clinical oncology 30 (33), 4117-4123, 2012 | 127 | 2012 |
| Changes in the influence of lymphoma-and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma SK Barta, MS Samuel, X Xue, D Wang, JY Lee, N Mounier, JM Ribera, ... Annals of Oncology 26 (5), 958-966, 2015 | 115 | 2015 |
| Clinical characteristics of monkeypox virus infections among men with and without HIV: a large outbreak cohort in Germany C Hoffmann, H Jessen, C Wyen, S Grunwald, S Noe, J Teichmann, ... HIV medicine 24 (4), 389-397, 2023 | 106 | 2023 |
| Progressive multifocal leukencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death C Wyen, C Hoffmann, N Schmeier, A Wöhrmann, N Qurishi, J Rockstroh, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 37 (2), 1263-1268, 2004 | 99 | 2004 |
| The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women APH Colbers, DA Hawkins, A Gingelmaier, K Kabeya, JK Rockstroh, ... Aids 27 (5), 739-748, 2013 | 94 | 2013 |
| Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients M Van Der Lee, R Sankatsing, E Schippers, M Vogel, G Fätkenheuer, ... Antiviral therapy 12 (7), 1127-1132, 2007 | 91 | 2007 |
| Efficacy and safety of switching to dolutegravir/lamivudine versus continuing a tenofovir alafenamide–based 3-or 4-drug regimen for maintenance of virologic suppression in … O Osiyemi, S De Wit, F Ajana, F Bisshop, J Portilla, JP Routy, C Wyen, ... Clinical Infectious Diseases 75 (6), 975-986, 2022 | 90 | 2022 |
| Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P‐glycoprotein in HIV‐infected patients C Wyen, U Fuhr, D Frank, RE Aarnoutse, T Klaassen, A Lazar, ... Clinical Pharmacology & Therapeutics 84 (1), 75-82, 2008 | 86 | 2008 |
| Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study P Schommers, C Wyen, M Hentrich, D Gillor, A Zoufaly, B Jensen, ... Aids 27 (5), 842-845, 2013 | 77 | 2013 |
| Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals A Schipani, C Wyen, T Mahungu, H Hendra, D Egan, M Siccardi, ... Journal of antimicrobial chemotherapy 66 (6), 1332-1339, 2011 | 73 | 2011 |
